Connect your AI

MapLight Therapeutics, Inc. MPLT Investments

Investments at other companies

AbbVieABBV

——

Mirum Pharmaceuticals, Inc.MIRM

——

Other financials

Income statement

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

Market cap$1.39B+100%

Enterprise value$1.34B—

Returns & leverage

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermInvestments.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is MapLight Therapeutics, Inc. 's investments?: MapLight Therapeutics, Inc. (MPLT) reported investments of $85.09M in Q1 2026.